Fig. 1From: Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 dataInitial dose-toxicity curves and 95 % prediction intervals from prior skeleton approaches. The predicted probabilities of experiencing a DLT and corresponding 95 % prediction intervals for each prior skeleton approach used in the extended CRM method prior to the inclusion of any dose-toxicity dataBack to article page